TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

The purpose of this clinical trial is to assess the safety and tolerability of TTFields in combination with chemotherapy in adults with metastatic pancreatic adenocarcinoma based on treatment-emergent adverse events of chemotherapy (modFOLFIRINOX) or device (TTFields). The main questions it aims to answer are: * Is TTFields treatment safe for the patients in combination with modFOLFIRINOX? * Are participants compliant with the treatment? * Is Is TTFields treatment effective in combination with modFOLFIRINOX against metastatic pancreatic adenocarcinoma?

Trial Details

NCT ID
NCT07284277
Phase
PHASE1 / PHASE2
Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • TTFields concomitant with modFOLFIRINOX
Locations (sample)
  • Pamplona, Navarre, Spain|42.81687,-1.64323
  • Barakaldo, Vizcaya, Spain|43.29639,-2.98813
  • Galdakao, Vizcaya, Spain|43.23073,-2.8429
  • Madrid, Spain|40.4165,-3.70256
  • Vitoria-Gasteiz, Álava, Spain|42.84998,-2.67268

Key Eligibility Criteria

  • All the patients should comply with the following criteria for inclusion:
  • Histological/cytological diagnosis of pancreatic adenocarcinoma.
  • The patient should be 18 years of age and older.
  • The patient has given consent to participate in the study.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →